Developed by Moscow's Gamaleya Institute, the Russian Defence Ministry and the Russian Direct Investment Fund (RIDF), Sputnik V is based on a modified human adenovirus as the vector which carries the SARS-CoV-2 virus protein.
The same day, it was reported that Delhi-based Mankind Pharma had signed an agreement with the Russian Direct Investment Fund (RIDF) for the distribution and sale of Sputnik V in India.
More on Covid-19Dr Reddy's co-chairman and managing director G V Prasad termed it as a significant development that will allow the company to commence the clinical trials for Sputnik V in India.
Dr. Jadhav said, "We can produce 700-800 million vaccine doses every year once things are streamlined". Its vaccine is in late stage trials in Brazil, Indonesia and Turkey, and the company has said that an interim analysis of Phase 3 trial data could come as early as November.
RDIF CEO Kirill Dmitrev said that in addition to Indian clinical trials data, RDIF will provide safety and immunogenicity study from the Russian Phase-3 clinical trial as well. While Sputnik V is now undergoing Phase-3 clinical trials involving 40,000 volunteers in Russian Federation, a Phase-3 clinical trial of the vaccine has also commenced in the UAE last week.
The phase 3 efficacy trials are expected to take longer as researchers have to wait for sets of volunteers to develop the coronavirus disease and demonstrate that the proportion falling ill in the recipients' group is significantly smaller than those in the non-recipients' group.
Russian Federation has registered a second vaccine - EpiVacCorona, while a third vaccine has received permission to conduct first and second stages of clinical trials at medical facilities in Novosibirsk, St Petersburg and Kirov.
Authorities did not say how many people in the city had been given the vaccine, which comes in two doses, administered up to 28 days apart and costing a total of 400 yuan ($59).
As part of the partnership, RDIF is set to supply 100 million doses of the vaccine to Dr Reddy's upon regulatory approval in India, IANS, an independent newswire, report said on Saturday.
Chairing a meeting to review the COVID-19 pandemic situation and the preparedness of vaccine delivery, distribution, and administration, the prime minister also noted a steady decline in the daily cases and the growth rate.